LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
MLSS
Milestone Scientific Inc.
There isn't enough reported data to score MLSS yet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
MLSS Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Unavailable | |
| Unavailable |
MLSS's revenue is currently healthy, but its profitability is under pressure. There isn't enough data to rate its cash flow and balance sheet.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
MLSS PE Valuation
MLSS has no meaningful PE right now: it lost money over the past year.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
MLSS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect MLSS's losses to shrink, with revenue growing.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over MLSS on earnings quality, reporting a profit while its opponent remains loss making.
MLSS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$0.05 | +$0.04 |
| Q1 2026 | -$0.06 | +$0.01 |
| Q4 2025 | -$0.07 | $0.00 |
| Q3 2025 | -$0.08 | -$0.01 |
| Q2 2025 | -$0.09 | -$0.02 |
| Q1 2025 | -$0.07 | +$0.03 |
| Q4 2024 | -$0.07 | +$0.03 |
| Q3 2024 | -$0.07 | +$0.03 |
MLSS is still losing money, but far less than before: $0.05 per share over the past year, against $0.21 at its worst in mid-2020.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over MLSS on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over MLSS on profitability, with a higher operating margin.
MLSS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $2.8M | +22% |
| Q1 2026 | $2.2M | -3.2% |
| Q4 2025 | $2.1M | +2.2% |
| Q3 2025 | $2.4M | -6.1% |
| Q2 2025 | $2.3M | +25% |
| Q1 2025 | $2.2M | -0.7% |
| Q4 2024 | $2M | -11% |
| Q3 2024 | $2.5M | +22% |
MLSS's revenue has held roughly level: $3M last quarter, up 22% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -37% | +27 points |
| Q1 2026 | -38% | +51 points |
| Q4 2025 | -52% | +49 points |
| Q3 2025 | -48% | +10 points |
| Q2 2025 | -64% | +32 points |
| Q1 2025 | -89% | -24 points |
| Q4 2024 | -101% | -14 points |
| Q3 2024 | -58% | +15 points |
MLSS's operating margin was −37% last quarter, up 27 points from the same quarter a year ago, near the top of its range since 2019.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the stronger cash trend. Its trailing FCF is up 259% versus its history, compared with MLSS at up 46%.
MLSS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$589.3K | +$1.2M |
| Q1 2026 | $85.2K | +$1.1M |
| Q4 2025 | -$229.2K | +$1.3M |
| Q2 2025 | -$1.8M | -325% |
| Q1 2025 | -$1M | +$210K |
| Q4 2024 | -$1.5M | -$265.7K |
| Q3 2024 | -$973.9K | +$79.3K |
| Q2 2024 | $783.7K | +$1.8M |
MLSS has burned cash in almost every quarter: −$2M over the past year, against −$3M the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over MLSS on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
MLSS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +9.5% | +8.1M shares |
| 1 year | +13% | +11.1M shares |
| 3 years | +29% | +20.8M shares |
| 5 years | +35% | +23.9M shares |
| Available history | +95% | +45.4M shares |
MLSS has 93M diluted shares, up 13% from a year ago.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
MLSS Net Leverage
MLSS's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
MLSS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 37.9 | Neutral |
| Stochastic | 4.7 | Oversold |
MLSS's weekly RSI is 38 (neutral) and its Stochastic is 5 (oversold).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
MLSS PE vs Healthcare Sector
MLSS has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over MLSS on trend strength, trading above more of its moving averages.
MLSS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.33 | 12% below |
| 20 week MA | $0.39 | 26% below |
| 50 week MA | $0.35 | 17% below |
| 100 week MA | $0.57 | 49% below |
| 200 week MA | $0.70 | 59% below |
MLSS is in a downtrend: it's below all five of its weekly moving averages, and 59% below its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over MLSS on returns for 2026, with the stronger performance.
MLSS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $1.38 | $2.02 | +46% |
| 2021 | $2.02 | $2.13 | +5.4% |
| 2022 | $2.13 | $0.45 | -79% |
| 2023 | $0.45 | $0.69 | +53% |
| 2024 | $0.69 | $0.88 | +28% |
| 2025 | $0.88 | $0.29 | -67% |
| 2026 YTD | $0.29 | $0.29 | 0% |
MLSS has finished higher in four of the last six years. It's roughly flat so far in 2026.